Phaseline

Targets › APRIL

APRIL (Tumor necrosis factor ligand superfamily member 13): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Genitourinary; next expected readout Jun 2028.

Cytokine that binds to TNFRSF13B/TACI and to TNFRSF17/BCMA. Plays a role in the regulation of tumor cell growth. May be involved in monocyte/macrophage-mediated immunological processes. (UniProt, O75888)

Open in Phaseline: the race on APRIL, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Beijing Mabworks BiotechMIL116
anti-APRIL monoclonal antibody
APRILPhase 1Immunoglobulin A NephropathyJun 2028

Conditions

Immunoglobulin A Nephropathy (1)

Modalities

small molecule (1)

Companies

Beijing Mabworks Biotech (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.